Evaluation of serum autoantibody levels in the diagnosis of ovarian endometrioma

Yi YC, Yu‐Chiao Yi, Yu-Chiao Yi, Shih-Chi Wang, Shih‐Chi Wang, Wang SC, Chun‐Chin Chao, Chun-Chin Chao, Chao CC, Chia‐Ling Su, Chia-Ling Su, Su CL, Lee YL, Yao-Ling Lee, Yao‐Ling Lee, Chen LY, Lingyun Chen, Ling-Yun Chen
Journal of clinical laboratory analysis · 2010 · vol. 24(5) , pp. 357–362 · doi:10.1002/jcla.20415 · PMID:20872572 · PMC6647576 · W1997544588
article OA: bronze CC0 ⤵ 10 in-corpus citations
📄 Open PDF View on OpenAlex View on PubMed View at publisher
⚙ AI-generated summary by gemini-2.5-flash-lite, 2026-06-12 ⓘ

Serum IMP1 autoantibodies alone or combined with cyclin B1 autoantibodies showed potential diagnostic accuracy for ovarian endometrioma in this study.

One-sentence paraphrase of the abstract; not a substitute for reading it. No clinical advice. How this works

Abstract

OBJECTIVE: We analyzed autoantibodies against tumor-associated antigens (TAAs) in the serum of patients with endometrioma and healthy controls to determine whether autoantibodies can be accurate biomarkers for the diagnosis of ovarian endometrioma. METHODS: Serum samples were obtained from 56 patients with endometriosis and 66 healthy women who served as normal controls. The titers of antibodies against a panel of eight TAAs were analyzed using enzyme-linked immunosorbent assay. RESULTS: We found that the serum IGFII mRNA-binding protein 1 (IMP1) autoantibody and cyclin B1 autoantibody could discriminate between healthy controls and endometriosis patients (AUC-ROC 0.777; 95% confidence interval [CI] 0.694-0.860, P<0.0005, and AUC-ROC 0.614; 95%confidence interval [CI] 0.513-0.714, P=0.031, respectively). Using 0.073 and 0.007 as the cutoff values for IMP1 and Cyclin B1 autoantibody, respectively, the sensitivity and specificity of IMP1 were 85.7 and 63.6%, respectively. When cylcin B1 was combined with IMP1, the specificity increased to 72.7% and the sensitivity slightly decreased to 83.9%. CONCLUSIONS: Our data suggest that IMP1 alone or combined with cyclin B1 seems to fulfill the requirements of sensitivity and specificity to become a useful clinical biomarker of endometrioma. However, further studies will be required to establish the predictive value and to support the clinical use of IMP1/cyclin B1 in the diagnosis and/or screening of endometriosis.

My notes (saved in your browser only)

Condition tags

endometriosisendometrioma

MeSH descriptors

Autoantibodies Biomarkers, Tumor Cyclin B1 Endometriosis Ovarian Neoplasms RNA-Binding Proteins Adolescent Adult Autoantibodies Biomarkers, Tumor Case-Control Studies Cyclin B1 Endometriosis Enzyme-Linked Immunosorbent Assay Female Humans Middle Aged Ovarian Neoplasms Prognosis RNA-Binding Proteins

Citation neighborhood

Papers in the corpus that this work cites (lower rings, blue) and that cite this one (upper rings, green). Dot size scales with the paper's in-corpus citation count — bigger dot = more influential within the endo/adeno field. Click a dot to open that paper. [ expand to 2 hops ] — adds papers reached through this work's immediate citers/citees. Heavier; up to 60 extra dots.

References (31)

Cited by (10)

Source provenance

europepmc
last seen: 2026-09-13T09:25:22.628771+00:00
openalex
last seen: 2026-06-10T17:14:06.276822+00:00
pubmed
last seen: 2026-05-13T22:17:00.782903+00:00
License: CC0 · commercial use OK